

7. The antibody of claim 6, wherein said antibody comprises three variable heavy (VH) complementarity determining regions (CDRs) listed in Table 4 (nucleotides 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74),

8. The antibody of claim 1, wherein said antibody further comprises a variable light (VL) complementarity determining region (CDR) listed in Table 4 (nucleotides 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74, or nucleotides 24-33, 49-55, or 88-96 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, or 90, or nucleotides 24-35, 51-57, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, or 98, or nucleotides 24-38, 54-60, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, or 92-95).

9. The antibody of claim 8, wherein said antibody comprises at least two variable light (VL) complementarity determining regions (CDRs) listed in Table 4 (nucleotides 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74, or nucleotides 24-33, 49-55, or 88-96 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, or 90, or nucleotides 24-35, 51-57, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, or 98, or nucleotides 24-38, 54-60, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, or 92-95).

10. The antibody of claim 9, wherein said antibody comprises three variable light (VL) complementarity determining regions (CDRs) listed in Table 4 (nucleotides 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74, or nucleotides 24-33, 49-55, or 88-96 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, or 90, or nucleotides 24-35, 51-57, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, or 98, or nucleotides 24-38, 54-60, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, or 92-95).

17. The antibody of claim 1, wherein said antibody comprises a framework region listed in Table 4 (nucleotides 1-30, 36-49, 67-98, or 115-125 of any of SEQ ID NOS:51-74, nucleotides 1-23, 34-48, 56-87, or 97-107 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, and 90, nucleotides 1-23, 36-50, 58-89, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, and 98, or nucleotides 1-23, 39-53, 61-92, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, and 92-95).

18. The antibody of claim 17, wherein said framework is a variable heavy (VH) framework region listed in Table 4 (nucleotides 1-30, 36-49, 67-98, or 115-125 of any of SEQ ID NOS:51-74).

19. The antibody of claim 17, wherein said framework is a variable light (VL) framework region listed in Table 4 (nucleotides 1-23, 34-48, 56-87, or 97-107 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, and 90, nucleotides 1-23, 36-50, 58-89, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, and 98, or nucleotides 1-23, 39-53, 61-92, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, and 92-95).

20. The antibody of claim 18, wherein said antibody comprises at least two variable heavy (VH) framework regions listed in Table 4 (nucleotides 1-30, 36-49, 67-98, or 115-125 of any of SEQ ID NOS:51-74).

21. The antibody of claim 19, wherein said antibody comprises at least two variable light (VL) framework regions listed in Table 4 (nucleotides 1-23, 34-48, 56-87, or 97-107 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, and 90, nucleotides 1-23, 36-50, 58-89, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, and 98, or nucleotides 1-23, 39-53, 61-92, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, and 92-95).

22. The antibody of claim 18, wherein said antibody comprises a variable heavy (VH) region listed in Table 4 (SEQ ID NOS:51-74).

23. The antibody of claim 19, wherein said antibody comprises a variable light (VL) region listed in Table 4 (SEQ ID NOS:75-98).

24. (Once amended) An isolated single chain anti-botulinum neurotoxin type A (anti-BoNT/A) antibody, said antibody comprising a variable heavy (VH) complementarity determining region (CDR) listed in Table 4 (nucleotides 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74), and wherein said antibody specifically binds to and neutralizes a botulinum neurotoxin type A.

25. The antibody of claim 24, wherein said antibody comprises at least two variable heavy (VH) complementarity determining regions (CDRs) listed in Table 4 (nucleotides 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74).

26. The antibody of claim 25, wherein said antibody comprises at three variable heavy (VH) complementarity determining regions (CDRs) listed in Table 4 (nucleotides 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74).

27. The antibody of claim 24, wherein said antibody further comprises a variable light (VL) complementarity determining region (CDR) listed in Table 4 (nucleotides 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74, or nucleotides 24-33, 49-55, or 88-96 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, or 90, or nucleotides 24-35, 51-57, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, or 98, or nucleotides 24-38, 54-60, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, or 92-95).

28. The antibody of claim 27, wherein said antibody comprises at least two variable light (VL) complementarity determining regions (CDRs) listed in Table 4 (nucleotides 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74, or nucleotides 24-33, 49-55, or 88-96 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, or 90, or nucleotides 24-35, 51-57, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, or 98, or nucleotides 24-38, 54-60, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, or 92-95).

29. The antibody of claim 28, wherein said antibody comprises three variable light (VL) complementarity determining regions (CDRs) listed in Table 4 (nucleotides 31-35, 50-66, or 99-114 of any of SEQ ID NOS:51-74, or nucleotides 24-33, 49-55, or 88-96 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, or 90, or nucleotides 24-35, 51-57, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, or 98, or nucleotides 24-38, 54-60, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, or 92-95).

36. The antibody of claim 24, wherein said antibody comprises a framework region listed in Table 4 (nucleotides 1-30, 36-49, 67-98, or 115-125 of any of SEQ ID NOS:51-74, nucleotides 1-23, 34-48, 56-87, or 97-107 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, and 90,

nucleotides 1-23, 36-50, 58-89, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, and 98, or nucleotides 1-23, 39-53, 61-92, or 102-112 of any of SEQ ID NOS: 80, 81, 84-87, and 92-95).

37. The antibody of claim 36, wherein said framework is a variable heavy (VH) framework region listed in Table 4 (nucleotides 1-30, 36-49, 67-98, or 115-125 of any of SEQ ID NOS:51-74).

38. The antibody of claim 36, wherein said framework is a variable light (VL) framework region listed in Table 4 (nucleotides 1-23, 34-48, 56-87, or 97-107 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, or 90, nucleotides 1-23, 36-50, 58-89, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, or 98, nucleotides 1-23, 39-53, 61-92, or 102-112 of any or SEQ ID NOS: 80, 81, 84-87, or 92-95).

39. The antibody of claim 37, wherein said antibody comprises at least two variable heavy (VH) framework regions listed in Table 4 (nucleotides 1-30, 36-49, 67-98, or 115-125 of any of SEQ ID NOS:51-74).

40. The antibody of claim 38, wherein said antibody comprises at least two variable light (VL) framework regions listed in Table 4 (nucleotides 1-23, 34-48, 56-87, or 97-107 of any of SEQ ID NOS:75, 76, 78, 82, 83, 88, or 90, nucleotides 1-23, 36-50, 58-89, or 99-109 of any of SEQ ID NOS: 77, 79, 91, 96, 97, or 98, nucleotides 1-23, 39-53, 61-92, or 102-112 of any or SEQ ID NOS: 80, 81, 84-87, or 92-95).

41. The antibody of claim 37, wherein said antibody comprises a variable heavy (VH) region listed in Table 4 (SEQ ID NOS:51-74).

42. The antibody of claim 38, wherein said antibody comprises a variable light (VL) region listed in Table 4 (SEQ ID NOS:75-98).

Please add the following new claim 77: